Test Price
2,800 AED✅ Home Collection Available
NR3C2 Gene Pseudohypoaldosteronism Type 1, Autosomal Dominant Genetic Test in UAE – 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Our internationally accredited laboratory delivers 99.9% diagnostic sensitivity for the NR3C2 gene using next‑generation sequencing (NGS) with CNV analysis, fully licensed by the Dubai Health Authority (DHA) and ISO 9001:2015 certified.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited processing and dual‑strand bioinformatics verification.
- Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
- Clinical Guidance: Post‑test telephonic result interpretation with a DHA‑licensed genetic counsellor to support informed clinical decisions.
- Insurance & Billing: Direct billing verification available via WhatsApp +971 54 548 8731; self‑pay price 2,800 AED inclusive of all laboratory fees.
Test Overview & Methodology
This comprehensive next‑generation sequencing (NGS) test analyzes the NR3C2 gene (NM_000901.4) to detect sequence variants and copy‑number variations (CNVs) responsible for autosomal dominant pseudohypoaldosteronism type 1 (PHA1). PHA1 presents as a renal salt‑wasting disorder with hyperkalemia, hyponatremia, and elevated aldosterone, often mimicking other endocrine conditions. Definitive genetic diagnosis guides targeted therapy, enables family cascade screening, and supports long‑term management planning for UAE patients.
| Feature | Our Test (NR3C2 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) with CNV analysis | Targeted Sanger sequencing of coding exons only |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Coverage | Full gene, including deep intronic and copy‑number changes | Exon‑focused, misses large rearrangements |
| Price (AED) | 2,800 | ~4,000 |
Physician Insight & Safety Protocols
"This NGS test is a powerful diagnostic tool for autosomal dominant pseudohypoaldosteronism type 1. However, a normal result does not exclude other salt‑wasting nephropathies. Clinicians should always correlate genetic findings with serum electrolytes, aldosterone, renin activity, and a detailed family pedigree. I strongly recommend pre‑ and post‑test genetic counselling to navigate the implications of autosomal dominant inheritance."
Lina Osama Zaki Quteineh
Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed mineralocorticoids, salt supplementation, or any other medications without consulting your attending physician. Test results should always be interpreted in the context of ongoing therapy.
Exclusion Criteria & Emergency Red Flags
- Known hematologic condition or severe anemia making venipuncture unsafe without medical clearance.
- Active systemic infection or hemodynamic instability requiring urgent care.
- ER Red Flags: Severe dehydration, cardiac arrhythmias, or shock—seek immediate emergency attention, not genetic testing.
- Test cannot be performed on patients who have undergone allogeneic bone marrow transplantation due to donor DNA interference.
Patient FAQ & Clinical Guidance
1. What is the NR3C2 gene test and why is it needed?
This NGS test identifies pathogenic variants in the NR3C2 gene causing pseudohypoaldosteronism type 1, enabling precise diagnosis of a salt‑wasting disorder that often mimics other endocrine conditions in UAE pediatric and adult patients. Early genetic confirmation allows targeted management and family cascade screening.
2. What sample is required and how is the collection performed?
We accept whole blood (3–5 mL in EDTA tube), extracted DNA (≥1 µg), or a single drop of blood on an FTA card. Sample collection can be arranged via our ISO‑certified home phlebotomy service, available daily from 8 AM to 11 PM, with temperature‑controlled cold‑chain transport to our DHA‑licensed laboratory in Dubai Healthcare City.
3. How should I prepare for the NR3C2 genetic test?
A mandatory pre‑test genetic counselling session is required to discuss family history, draw a pedigree, and obtain informed consent. Continue all prescribed medications unless your doctor advises otherwise. No fasting is needed for this blood test.
UAE Regulatory & Data Privacy Adherence
Accreditation & Compliance: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Our laboratory fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. Data security, patient confidentiality, and ethical genetic testing protocols are rigorously maintained.
Clinical & Logistical Metadata
| Test Name | NR3C2 Gene Full Sequence Analysis (Autosomal Dominant Pseudohypoaldosteronism Type 1) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) or extracted DNA; also accepts FTA card. VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection available daily 8 AM–11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV analysis |
| ICD‑10‑CM Code | E26.1, Z13.79, Z15.89 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians